ストックスクリーナーアプリを入手
7.32
0.27%
0.02
アフターアワーズ：
7.41
0.09
+1.23%
前日終値:
$7.30
開ける：
$7.28
24時間の取引高:
1.41M
Relative Volume:
0.71
時価総額：
$537.42M
収益：
$161.10M
当期純損益:
$-308.60M
株価収益率:
-1.5675
EPS:
-4.67
ネットキャッシュフロー:
$-259.90M
1週間 パフォーマンス:
+3.24%
1か月 パフォーマンス:
-3.43%
6か月 パフォーマンス:
-58.81%
1年 パフォーマンス:
-70.04%
1日の値動き範囲:
$7.2601
$7.53
1週間の範囲:
$6.955
$7.53
52週間の値動き範囲:
$5.90
$29.61
Arvinas Inc Stock (ARVN) Company Profile
ARVN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
7.32 | 526.40M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-02 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | ダウングレード | Truist | Buy → Hold |
| 2025-05-02 | ダウングレード | Jefferies | Buy → Hold |
| 2025-05-02 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-03-13 | ダウングレード | Goldman | Buy → Neutral |
| 2025-03-12 | ダウングレード | Wedbush | Outperform → Neutral |
| 2025-03-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-12-10 | 開始されました | BTIG Research | Buy |
| 2024-11-18 | 開始されました | Stephens | Overweight |
| 2024-02-28 | 繰り返されました | Oppenheimer | Outperform |
| 2024-02-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-02-01 | 開始されました | Goldman | Buy |
| 2023-12-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | アップグレード | Jefferies | Hold → Buy |
| 2023-11-20 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-10-23 | アップグレード | Wedbush | Neutral → Outperform |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2023-01-12 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-01-03 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | 開始されました | Barclays | Overweight |
| 2022-06-21 | 開始されました | Jefferies | Hold |
| 2022-05-09 | ダウングレード | Wedbush | Outperform → Neutral |
| 2022-04-28 | 開始されました | Credit Suisse | Outperform |
| 2022-04-06 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-02-11 | 再開されました | BMO Capital Markets | Outperform |
| 2022-02-10 | 開始されました | Wells Fargo | Overweight |
| 2022-01-19 | 開始されました | Goldman | Buy |
| 2021-12-07 | 開始されました | Cowen | Outperform |
| 2021-10-14 | 開始されました | SVB Leerink | Outperform |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-09-09 | 開始されました | BofA Securities | Buy |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-21 | 開始されました | Truist | Buy |
| 2021-03-31 | 開始されました | BMO Capital Markets | Outperform |
| 2020-12-14 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-06-01 | アップグレード | Citigroup | Neutral → Buy |
| 2020-05-12 | 開始されました | Oppenheimer | Perform |
| 2019-12-19 | 開始されました | H.C. Wainwright | Buy |
| 2019-11-25 | 開始されました | Guggenheim | Buy |
| 2019-10-24 | アップグレード | Goldman | Neutral → Buy |
| 2019-09-25 | 開始されました | Wedbush | Outperform |
| 2019-09-12 | 開始されました | BMO Capital Markets | Outperform |
| 2019-08-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-06-05 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2018-10-22 | 開始されました | Citigroup | Buy |
| 2018-10-22 | 開始されました | Goldman | Neutral |
| 2018-10-22 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Arvinas Inc (ARVN) 最新ニュース
Arvinas, Pfizer’s Vepdegestrant NDA Accepted by FDA for Breast Cancer Treatment - MSN
What institutional flow reveals about Arvinas Inc.2025 Key Lessons & Fast Exit and Entry Trade Guides - Newser
Published on: 2025-08-20 04:59:17 - Newser
Will Arvinas Inc. stock go up soon2025 Trading Volume Trends & Fast Moving Trade Plans - Newser
What Fibonacci levels say about Arvinas Inc. reboundPortfolio Value Summary & Low Drawdown Investment Ideas - Newser
Technical analysis overview for Arvinas Inc. stockWeekly Trade Analysis & Weekly Chart Analysis and Trade Guides - Newser
Multi asset correlation models including Arvinas Inc.2025 Analyst Calls & Verified Entry Point Detection - Newser
How high can Arvinas Inc. stock goPortfolio Value Report & Weekly Hot Stock Watchlists - Newser
Is Arvinas Inc. forming a reversal patternTrade Risk Summary & Long-Term Safe Investment Plans - Newser
Statistical indicators supporting Arvinas Inc.’s strength2025 Volatility Report & Weekly High Momentum Picks - Newser
Using Ichimoku Cloud for Arvinas Inc. technicals2025 Sector Review & Accurate Entry/Exit Alerts - Newser
What makes Arvinas Inc. stock price move sharplyMarket Movers & Technical Buy Zone Confirmation - Newser
Arvinas Inc. Nearing Breakout Level After Bounce2025 Key Lessons & Fast Gain Swing Alerts - sundaytimes.kr
Arvinas Inc. Consolidation Zone May Signal Accumulation2025 Risk Factors & Technical Pattern Recognition Alerts - kangso.co.kr
Biotech's Big Comeback: 4 Stocks Poised to Ride the Resurgence (MDCX, ARVN, RYTM, ENTA) - MarketScreener
How institutional ownership impacts Arvinas Inc. stockPortfolio Performance Report & Reliable Intraday Trade Plans - Newser
What high frequency data says about Arvinas Inc.Portfolio Return Report & Free Expert Approved Momentum Trade Ideas - Newser
Should you wait for a breakout in Arvinas Inc.Breakout Watch & High Return Trade Guides - Newser
Strategies to average down on Arvinas Inc.July 2025 Setups & Detailed Earnings Play Strategies - Newser
Bank of America Securities Reiterates Buy Rating for Arvinas Holding Company - AInvest
Is Arvinas Inc. a speculative investmentMarket Movers & Daily Risk Controlled Trade Plans - thegnnews.com
Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Arvinas Inc. stock daily chart insightsPortfolio Growth Summary & Stepwise Trade Execution Plans - Newser
Arvinas Inc.’s Price Action Aligns with Quant Signals2025 Key Highlights & Safe Capital Growth Tips - 선데이타임즈
FY2025 EPS Estimates for Arvinas Cut by Cantor Fitzgerald - MarketBeat
Can Arvinas Inc. scale operations efficientlyJuly 2025 Spike Watch & Free Safe Entry Trade Signal Reports - classian.co.kr
HC Wainwright Comments on Arvinas' Q3 Earnings (NASDAQ:ARVN) - MarketBeat
Leerink Partnrs Analysts Cut Earnings Estimates for Arvinas - MarketBeat
Wedbush Has Optimistic Outlook of Arvinas Q3 Earnings - MarketBeat
Arvinas Inc. Stock Approaches Key Moving AverageMarket Growth Summary & Weekly High Momentum Picks - newsimpact.co.kr
Will Arvinas Inc. stock benefit from AI tech trendsForecast Cut & Advanced Swing Trade Entry Plans - Newser
Arvinas’s SWOT analysis: protein degrader stock faces pivotal moment By Investing.com - Investing.com Nigeria
Arvinas’s SWOT analysis: protein degrader stock faces pivotal moment - Investing.com
Arvinas, Inc. (NASDAQ:ARVN) Receives $19.76 Consensus PT from Analysts - MarketBeat
Custom watchlist performance reports with Arvinas Inc.Take Profit & Capital Efficiency Focused Ideas - Newser
Using data filters to optimize entry into Arvinas Inc.Fundamental + Technical Combined Watchlist - Newser
Arvinas (NASDAQ:ARVN) Given New $15.00 Price Target at Guggenheim - MarketBeat
Arvinas (NASDAQ:ARVN) Releases Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
HC Wainwright Has Lowered Expectations for Arvinas (NASDAQ:ARVN) Stock Price - MarketBeat
Is Arvinas Inc. Stock a Good Fit for Conservative InvestorsFree Real Time Stock Movement Analysis - Newser
Metastatic Prostate Cancer Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Merck Sharp & Dohme, Arvinas Androgen Receptor, UNICANCER, Aragon Pharma, Mark Stein, Novartis, Orion - Barchart.com
Pfizer and Arvinas' breast cancer therapy to be reviewed by FDA - MSN
FDA gives Arvinas and Pfizer’s vepdegestrant NDA for breast cancer - Yahoo Finance
Wedbush Issues Positive Forecast for Arvinas Earnings - Defense World
HC Wainwright Comments on Arvinas’ Q3 Earnings (NASDAQ:ARVN) - Defense World
Arvinas, Inc. (NASDAQ:ARVN) Shares Acquired by XTX Topco Ltd - MarketBeat
Arvinas Inc (ARVN) 財務データ
収益
当期純利益
現金流量
EPS
0.94%
1.72%
大文字化:
|
ボリューム (24 時間):